![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
J Casals-Stenzel, G Muacevic and KH Weber
WEB 2086, a thieno-triazolodiazepine, is a potent and specific antagonist of platelet activating factor (PAF) in vitro and in vivo. This compound inhibits PAF-induced human platelet and neutrophil aggregation in vitro (IC50 = 0.17 and 0.36 microM, respectively) but has little or no effect on the action of other platelet aggregating agents. In comparison with kadsurenone, ketotifen or thiazinamium chloride, WEB 2086 was 26 to 200 times more potent in the PAF-induced platelet aggregation. In anesthetized guinea pigs, pretreatment with 0.1 to 2.0 mg/kg p.o. or 0.01 to 0.5 mg/kg i.v. of WEB 2086 inhibits dose-dependently the accumulation and aggregation of 111Indium labeled platelets, bronchoconstriction, systemic hypotension and also the lethal effect due to an i.v. PAF infusion [30 ng/(kg X min)] or intratracheal instillation of PAF (300 micrograms/kg). Under the same experimental conditions in guinea pigs, WEB 2086 given by inhalation achieved a similar anti-PAF activity. In anesthetized rats, the hypotension induced by an i.v. PAF infusion was also reversed (ED50 = 0.052 mg/kg i.v.). The increase in cutaneous vascular permeability due to intradermal PAF (25 ng/site) was inhibited dose-dependently by WEB 2086 (0.025-2 micrograms/site) in rats. Because of its structural relationship to triazolodiazepines, WEB 2086 was examined for anticonvulsant and sedative action. Up to doses of 300 and 800 mg/kg p.o., respectively, no effects were found. In conclusion, WEB 2086 is a potent and specific PAF antagonist with triazolodiazepine structure but without sedative activity.
This article has been cited by other articles:
|
|
 |
|
  C. E. King-VanVlack, J. D. Mewburn, C. K. Chapler, and P. H. MacDonald Hemodynamic and proinflammatory actions of endothelin-1 in guinea pig small intestine submucosal microcirculation Am J Physiol Gastrointest Liver Physiol, June 1, 2003; 284(6): G940 - G948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. J. Dupre, C. Le Gouill, M. Rola-Pleszczynski, and J. Stankova Inverse Agonist Activity of Selected Ligands of Platelet-Activating Factor Receptor J. Pharmacol. Exp. Ther., October 1, 2001; 299(1): 358 - 365. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Montrucchio, G. Alloatti, and G. Camussi Role of Platelet-Activating Factor in Cardiovascular Pathophysiology Physiol Rev, October 1, 2000; 80(4): 1669 - 1699. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Subbanagounder, N. Leitinger, P. T. Shih, K. F. Faull, and J. A. Berliner Evidence That Phospholipid Oxidation Products and/or Platelet-Activating Factor Play an Important Role in Early Atherogenesis : In Vitro and In Vivo Inhibition by WEB 2086 Circ. Res., August 20, 1999; 85(4): 311 - 318. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Ishii, T. Kuwaki, T. Nagase, K. Maki, F. Tashiro, S. Sunaga, W.-H. Cao, K. Kume, Y. Fukuchi, K. Ikuta, et al. Impaired Anaphylactic Responses with Intact Sensitivity to Endotoxin in Mice Lacking a Platelet-activating Factor Receptor J. Exp. Med., June 1, 1998; 187(11): 1779 - 1788. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Sugiyama, K. Kugiyama, N. Ogata, H. Doi, Y. Ota, M. Ohgushi, T. Matsumura, H. Oka, and H. Yasue Biphasic Regulation of Transcription Factor Nuclear Factor-{kappa}B Activity in Human Endothelial Cells by Lysophosphatidylcholine Through Protein Kinase C–Mediated Pathway Arterioscler. Thromb. Vasc. Biol., April 1, 1998; 18(4): 568 - 576. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. J. Getting, R. J. Flower, L. Parente, R. d. Médicis, A. Lussier, B. A. Woliztky, M. A. Martins, and M. Perretti Molecular Determinants of Monosodium Urate Crystal-Induced Murine Peritonitis: A Role for Endogenous Mast Cells and a Distinct Requirement for Endothelial-Derived Selectins J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 123 - 130. [Abstract] [Full Text]
|
|
|
|
|
|
T. A. Hinterleitner, J. D. Valentich, J.-H. Cha, P. Will, A. Welton, and D. W. Powell J. Pharmacol. Exp. Ther., June 1, 1997; 281(3): 1264 - 1271. [Abstract] [Full Text]
|
|
|
|
|
|
M. Merlos, M. Giral, D. Balsa, R. Ferrando, M. Queralt, A. Puigdemont, J. García-Rafanell, and J. Forn Rupatadine, a New Potent, Orally Active Dual Antagonist of Histamine and Platelet-Activating Factor (PAF) J. Pharmacol. Exp. Ther., January 1, 1997; 280(1): 114 - 121. [Abstract] [Full Text]
|
|
|
|
 |
|
 Z. Pan, V. V. Kravchenko, and R. D. Ye Platelet-activating Factor Stimulates Transcription of the Heparin-binding Epidermal Growth Factor-like Growth Factor in Monocytes J. Biol. Chem., April 7, 1995; 270(14): 7787 - 7790. [Abstract] [Full Text] [PDF]
|
|
 |
 |
 |
|
 |
 |
 |
